Journal Article

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms

Tanus-Santos, Jose E., Palei, Ana C. T., Eleuterio, Nibia, Cavalli, Ricardo C., Sandrim, Valeria C.

2015

Overview

Introduction Vascular endothelial growth factor (VEGF) is relevant for healthy pregnancy, and abnormalities in VEGF functions have been associated with hypertensive disorders of pregnancy. Our group recently demonstrated that VEGF genetic polymorphisms affect the susceptibility to preeclampsia (PE). Objective Therefore, in this study our aim is to examine whether VEGF polymorphisms affect the antihypertensive responses in women with PE. Methods We studied 113 white PE women who were stratified according to blood pressure levels after antihypertensive treatment (46 responsive, R group and 67 non-responsive, NR group). We then compared the frequencies of two VEGF genetic polymorphisms (C-2578A and G-634C) between R and NR groups. Results We found no significant differences in genotype or allele distributions between R and NR groups ( P  > 0.05). In addition, no difference was observed in overall distribution of haplotypes ( P  > 0.05). Conclusion Our data suggest that VEGF polymorphisms do not affect responsiveness to the antihypertensive therapy in PE.

• Publisher: Springer Berlin Heidelberg,Springer Nature B.V
• Subject: Adult / Alleles / Antihypertensive Agents - therapeutic use / Endocrinology / Female / Genetic Predisposition to Disease / Genotype / Gynecology / Haplotypes / Human Genetics / Humans / Hypertension - complications / Hypertension - drug therapy / Hypertension - genetics / Maternal-Fetal Medicine / Medicine / Medicine & Public Health / Obstetrics/Perinatology/Midwifery / Polymorphism, Genetic / Pre-Eclampsia - genetics / Preeclampsia / Pregnancy / Treatment Outcome / Vascular endothelial growth factor / Vascular Endothelial Growth Factor A - genetics / Young Adult